[
  {
    "bcr_patient_uuid": "D1AA9C1A-D732-48C0-B669-8A14E0397344",
    "patient_ID": "TCGA.2Y.A9GV",
    "bcr_drug_barcode": "TCGA-2Y-A9GV-D66920",
    "bcr_drug_uuid": "2ED70472-0453-4F85-9A75-C8A9A6BDD3A9",
    "form_completion_date": "2014-11-3",
    "pharmaceutical_therapy_drug_name": "NAXAVAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 2233,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2304,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0E8C3831-DEF9-4EFA-9F93-8942072D6A77",
    "patient_ID": "TCGA.2Y.A9GZ",
    "bcr_drug_barcode": "TCGA-2Y-A9GZ-D66953",
    "bcr_drug_uuid": "858BC16D-D48D-46AE-8C07-FBD8A5DF9D01",
    "form_completion_date": "2014-11-3",
    "pharmaceutical_therapy_drug_name": "NAXAVAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 719,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 842,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3528DD91-1A6D-4D41-A3EE-829C857CC904",
    "patient_ID": "TCGA.2Y.A9H8",
    "bcr_drug_barcode": "TCGA-2Y-A9H8-D67250",
    "bcr_drug_uuid": "A041658C-D57C-4048-B642-6BC1038DE85E",
    "form_completion_date": "2014-11-3",
    "pharmaceutical_therapy_drug_name": "NAXAVAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 398,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 491,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3528DD91-1A6D-4D41-A3EE-829C857CC904",
    "patient_ID": "TCGA.2Y.A9H8",
    "bcr_drug_barcode": "TCGA-2Y-A9H8-D67251",
    "bcr_drug_uuid": "D29ED18B-0AEF-4D85-B579-589538D17FC5",
    "form_completion_date": "2014-11-3",
    "pharmaceutical_therapy_drug_name": "EVEROLIMUS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 498,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 608,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "3528DD91-1A6D-4D41-A3EE-829C857CC904",
    "patient_ID": "TCGA.2Y.A9H8",
    "bcr_drug_barcode": "TCGA-2Y-A9H8-D68658",
    "bcr_drug_uuid": "300E5076-567C-411A-8977-EE9BCC5CE0B2",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "SOM 230",
    "pharmaceutical_therapy_type": "HORMONE THERAPY",
    "days_to_drug_start": 498,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 608,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "EFC3E5E4-0D8E-4BEF-A259-29F8ED21684F",
    "patient_ID": "TCGA.2Y.A9H9",
    "bcr_drug_barcode": "TCGA-2Y-A9H9-D67254",
    "bcr_drug_uuid": "3A75D221-5FD8-459B-B5CC-CC8FA03BD3F2",
    "form_completion_date": "2014-11-3",
    "pharmaceutical_therapy_drug_name": "NAXAVAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1017,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "94E387AE-B641-4E9F-BB53-22C7B2A9CCCB",
    "patient_ID": "TCGA.3K.AAZ8",
    "bcr_drug_barcode": "TCGA-3K-AAZ8-D64051",
    "bcr_drug_uuid": "53F09997-1A79-41DE-A307-66747EA290B2",
    "form_completion_date": "2014-8-25",
    "pharmaceutical_therapy_drug_name": "SARAFENIB",
    "days_to_drug_start": 212,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 304,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "94E387AE-B641-4E9F-BB53-22C7B2A9CCCB",
    "patient_ID": "TCGA.3K.AAZ8",
    "bcr_drug_barcode": "TCGA-3K-AAZ8-D69331",
    "bcr_drug_uuid": "4B86947A-374F-4EC2-8181-4C1BFBE93662",
    "form_completion_date": "2015-1-5",
    "pharmaceutical_therapy_drug_name": "REGORAFENIB",
    "days_to_drug_start": 304,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "00f209c3-041a-4c6e-8b0f-6383eb3c85fc",
    "patient_ID": "TCGA.BC.4073",
    "bcr_drug_barcode": "TCGA-BC-4073-D6868",
    "bcr_drug_uuid": "9E049E94-1D4F-49C4-9689-A93EF69D5B9D",
    "form_completion_date": "2010-12-21",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 81,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG/DAY",
    "drug_dose": 400,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 800
  },
  {
    "bcr_patient_uuid": "00f209c3-041a-4c6e-8b0f-6383eb3c85fc",
    "patient_ID": "TCGA.BC.4073",
    "bcr_drug_barcode": "TCGA-BC-4073-D30830",
    "bcr_drug_uuid": "63E0D664-0D86-4265-8609-3CA1E342E63B",
    "form_completion_date": "2012-4-17",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 166,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG/DAY",
    "drug_dose": 200,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "DOSE REDUCTION",
    "drug_total_dose": 400
  },
  {
    "bcr_patient_uuid": "dfa15fbe-bb14-40ce-afc6-70694112e3e2",
    "patient_ID": "TCGA.BC.A10Q",
    "bcr_drug_barcode": "TCGA-BC-A10Q-D9855",
    "bcr_drug_uuid": "13C1ADC9-69D2-4F78-AB39-39032DEE9E83",
    "form_completion_date": "2011-4-1",
    "pharmaceutical_therapy_drug_name": "TAMOXIFEN",
    "pharmaceutical_therapy_type": "HORMONE THERAPY",
    "days_to_drug_start": 359,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 408,
    "regimen_number": 1,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "dfa15fbe-bb14-40ce-afc6-70694112e3e2",
    "patient_ID": "TCGA.BC.A10Q",
    "bcr_drug_barcode": "TCGA-BC-A10Q-D9850",
    "bcr_drug_uuid": "1BBDDEC2-4EE9-40B6-B907-EE429CE7D03A",
    "form_completion_date": "2011-4-1",
    "pharmaceutical_therapy_drug_name": "MITOMYCIN C",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 217,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 217,
    "drug_cycles": 1,
    "pharma_type_other": "CHEMOEMBOLIZATION",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 5,
    "regimen_number": 1,
    "drug_route": "INHALATION",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 5
  },
  {
    "bcr_patient_uuid": "dfa15fbe-bb14-40ce-afc6-70694112e3e2",
    "patient_ID": "TCGA.BC.A10Q",
    "bcr_drug_barcode": "TCGA-BC-A10Q-D9848",
    "bcr_drug_uuid": "A0F6AA78-BFC6-40A0-9127-D0F7F9AA42CF",
    "form_completion_date": "2011-4-1",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 217,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 217,
    "drug_cycles": 1,
    "pharma_type_other": "CHEMOEMBOLIZATION",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 20,
    "regimen_number": 1,
    "drug_route": "INHALATION",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 20
  },
  {
    "bcr_patient_uuid": "dfa15fbe-bb14-40ce-afc6-70694112e3e2",
    "patient_ID": "TCGA.BC.A10Q",
    "bcr_drug_barcode": "TCGA-BC-A10Q-D10102",
    "bcr_drug_uuid": "E5E8B541-F299-40DF-A792-7514B166B09F",
    "form_completion_date": "2011-4-7",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 426,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 751,
    "regimen_number": 2,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "0bf5bbd4-d9e8-42a6-9ab5-f2c174dec12c",
    "patient_ID": "TCGA.BC.A10R",
    "bcr_drug_barcode": "TCGA-BC-A10R-D9866",
    "bcr_drug_uuid": "8A7781FE-13A4-4932-BBAF-7CD42290C62D",
    "form_completion_date": "2011-4-1",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 237,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 237,
    "drug_cycles": 1,
    "pharma_type_other": "CHEMOEMBOLIZATION",
    "regimen_number": 1,
    "drug_route": "INHALATION",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "39baf24a-4032-4c23-b3fe-2c50df1881f6",
    "patient_ID": "TCGA.BC.A10W",
    "bcr_drug_barcode": "TCGA-BC-A10W-D10105",
    "bcr_drug_uuid": "2234B152-15AA-4827-A697-FDAD95FD6285",
    "form_completion_date": "2011-4-7",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 82,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 85,
    "drug_cycles": 1,
    "regimen_number": 1,
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "F53A70D9-A774-4969-896E-2DCDD4D02A7A",
    "patient_ID": "TCGA.BC.A8YO",
    "bcr_drug_barcode": "TCGA-BC-A8YO-D57375",
    "bcr_drug_uuid": "B8B6D701-E9E5-44C2-9D90-692659730A0A",
    "form_completion_date": "2014-3-10",
    "pharmaceutical_therapy_drug_name": "NEXAVAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 54,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 186,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "56A82A56-0241-4D3D-9DE2-696B0C36DF91",
    "patient_ID": "TCGA.BW.A5NP",
    "bcr_drug_barcode": "TCGA-BW-A5NP-D42457",
    "bcr_drug_uuid": "164C944A-AF81-454A-BAAE-E3F547B863F9",
    "form_completion_date": "2014-3-26",
    "pharmaceutical_therapy_drug_name": "NEXAVAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 128,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 289,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5B32D3F4-9B88-42DE-AAAC-22D1D2F5CDE0",
    "patient_ID": "TCGA.CC.A8HV",
    "bcr_drug_barcode": "TCGA-CC-A8HV-D69786",
    "bcr_drug_uuid": "6872A373-FAF3-48CD-8D7D-A20B18E9A041",
    "form_completion_date": "2015-1-19",
    "pharmaceutical_therapy_drug_name": "NEXAVAR",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 158,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 188,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "45b566d7-f120-471c-a94a-be7936889f2d",
    "patient_ID": "TCGA.DD.A115",
    "bcr_drug_barcode": "TCGA-DD-A115-D42008",
    "bcr_drug_uuid": "3E81299F-E306-4CB2-910E-62C3C022D4A4",
    "form_completion_date": "2013-4-9",
    "clinical_trial_drug_classification": "PHASE II",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 502,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 841,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "0ef95351-0133-4f34-a59c-90934fb161f8",
    "patient_ID": "TCGA.DD.A11D",
    "bcr_drug_barcode": "TCGA-DD-A11D-D43740",
    "bcr_drug_uuid": "2DB8D5F3-1FDA-4725-86C3-2549F8DD8D73",
    "form_completion_date": "2013-6-2",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 586,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 641,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0ef95351-0133-4f34-a59c-90934fb161f8",
    "patient_ID": "TCGA.DD.A11D",
    "bcr_drug_barcode": "TCGA-DD-A11D-D43741",
    "bcr_drug_uuid": "4BBDB795-AA63-453D-88B3-677EB922902E",
    "form_completion_date": "2013-6-2",
    "pharmaceutical_therapy_drug_name": "ABT-888 AND TEMOZOLOMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 709,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1105,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "0ef95351-0133-4f34-a59c-90934fb161f8",
    "patient_ID": "TCGA.DD.A11D",
    "bcr_drug_barcode": "TCGA-DD-A11D-D43742",
    "bcr_drug_uuid": "D511991F-BE5E-4BF0-BD66-6448564DE07C",
    "form_completion_date": "2013-6-2",
    "pharmaceutical_therapy_drug_name": "TEMOZOLOMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1408,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1474,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "520a709a-87f6-4f3d-b2a2-9192e3b65c5b",
    "patient_ID": "TCGA.DD.A1EC",
    "bcr_drug_barcode": "TCGA-DD-A1EC-D42203",
    "bcr_drug_uuid": "A9E3B60E-52B2-4611-9D09-B6BC02287480",
    "form_completion_date": "2013-4-15",
    "clinical_trial_drug_classification": "PHASE III",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 330,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "6C79F64B-63FE-46F5-BF7B-77208231B0F2",
    "patient_ID": "TCGA.DD.A1EG",
    "bcr_drug_barcode": "TCGA-DD-A1EG-D43858",
    "bcr_drug_uuid": "55D863E7-C0D9-44E5-8BCE-EE5A1587A652",
    "form_completion_date": "2013-6-4",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1154,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1310,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "cab5b264-abab-4bdb-816e-9d2c0ac30629",
    "patient_ID": "TCGA.DD.A1EH",
    "bcr_drug_barcode": "TCGA-DD-A1EH-D45786",
    "bcr_drug_uuid": "3A35F09B-03D7-48FA-9823-F28D51834CD4",
    "form_completion_date": "2013-7-22",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 358,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 863,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "cab5b264-abab-4bdb-816e-9d2c0ac30629",
    "patient_ID": "TCGA.DD.A1EH",
    "bcr_drug_barcode": "TCGA-DD-A1EH-D45810",
    "bcr_drug_uuid": "7F848383-13AF-41E4-890D-56CDCC89F3F2",
    "form_completion_date": "2013-7-22",
    "pharmaceutical_therapy_drug_name": "DOXORUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 553,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 721,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "cab5b264-abab-4bdb-816e-9d2c0ac30629",
    "patient_ID": "TCGA.DD.A1EH",
    "bcr_drug_barcode": "TCGA-DD-A1EH-D45811",
    "bcr_drug_uuid": "2F99B152-0487-4404-BD4E-57B8429496BD",
    "form_completion_date": "2013-7-22",
    "pharmaceutical_therapy_drug_name": "EVEROLIMUS, GEMCITABINE, AND CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 862,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 975,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "52292ffc-0902-4d97-b461-20723987a177",
    "patient_ID": "TCGA.DD.A1EJ",
    "bcr_drug_barcode": "TCGA-DD-A1EJ-D42213",
    "bcr_drug_uuid": "432C8670-CC86-4488-92AC-E4C37DB72327",
    "form_completion_date": "2013-4-15",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 264,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 887,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "A5E4412B-0E49-4D86-9CCE-71F440A84048",
    "patient_ID": "TCGA.DD.A1EK",
    "bcr_drug_barcode": "TCGA-DD-A1EK-D42207",
    "bcr_drug_uuid": "91BF0C5B-D368-4354-930D-07933F900F0F",
    "form_completion_date": "2013-4-15",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 188,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 349,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AB35C9F9-3040-424D-A89F-DFF3A1365BC6",
    "patient_ID": "TCGA.DD.A3A4",
    "bcr_drug_barcode": "TCGA-DD-A3A4-D42698",
    "bcr_drug_uuid": "6A8F862A-4110-49E6-8866-C53975BFECBF",
    "form_completion_date": "2013-4-27",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 459,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 486,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "614C0ECF-6A84-4C86-8706-79BE5BB00991",
    "patient_ID": "TCGA.DD.A3A7",
    "bcr_drug_barcode": "TCGA-DD-A3A7-D42005",
    "bcr_drug_uuid": "30C072AE-2E51-4A99-82A1-9F7734A11DC5",
    "form_completion_date": "2013-4-9",
    "clinical_trial_drug_classification": "PHASE II",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 146,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 192,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "C0BF9278-9CBB-4361-B4D8-AB172B67E276",
    "patient_ID": "TCGA.DD.A4ND",
    "bcr_drug_barcode": "TCGA-DD-A4ND-D43026",
    "bcr_drug_uuid": "8E76F1B7-7EFB-4AF9-A238-BF6BDDD6587F",
    "form_completion_date": "2013-5-13",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN/CYTOXAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 20,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 218,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BCE25281-502E-4599-9679-32DC8462FFB1",
    "patient_ID": "TCGA.DD.A4NE",
    "bcr_drug_barcode": "TCGA-DD-A4NE-D43115",
    "bcr_drug_uuid": "8B7A43C8-CAD9-4752-846A-109156C0512A",
    "form_completion_date": "2013-5-13",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 225,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4012EA90-5768-4ACC-AF3A-BA954F493DB4",
    "patient_ID": "TCGA.DD.A4NH",
    "bcr_drug_barcode": "TCGA-DD-A4NH-D43119",
    "bcr_drug_uuid": "46FAF023-C8C4-42D9-9042-5DFA619DA676",
    "form_completion_date": "2013-5-13",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 162,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 305,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "C05720FE-19C1-4CFF-819B-6806B26FC312",
    "patient_ID": "TCGA.DD.A4NQ",
    "bcr_drug_barcode": "TCGA-DD-A4NQ-D43379",
    "bcr_drug_uuid": "AF94B879-0ED7-4F2A-A418-B3B3C6DA6FA0",
    "form_completion_date": "2013-5-20",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 151,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 290,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "A6A3F07C-CED4-451B-B2E5-C93E4ED622C1",
    "patient_ID": "TCGA.DD.A4NS",
    "bcr_drug_barcode": "TCGA-DD-A4NS-D43384",
    "bcr_drug_uuid": "4ECFB11B-261D-4F2A-9E49-090F4C27457C",
    "form_completion_date": "2013-5-20",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1116,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1314,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "A6A3F07C-CED4-451B-B2E5-C93E4ED622C1",
    "patient_ID": "TCGA.DD.A4NS",
    "bcr_drug_barcode": "TCGA-DD-A4NS-D43386",
    "bcr_drug_uuid": "05CF4554-4A7D-44D1-8AC1-B3A150B3961C",
    "form_completion_date": "2013-5-20",
    "pharmaceutical_therapy_drug_name": "ABT-888",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1349,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1425,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "A6A3F07C-CED4-451B-B2E5-C93E4ED622C1",
    "patient_ID": "TCGA.DD.A4NS",
    "bcr_drug_barcode": "TCGA-DD-A4NS-D43387",
    "bcr_drug_uuid": "13B7F0AF-30AA-4D7C-930B-06B8D9644F32",
    "form_completion_date": "2013-5-20",
    "pharmaceutical_therapy_drug_name": "LY228820",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1685,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1903,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "A6A3F07C-CED4-451B-B2E5-C93E4ED622C1",
    "patient_ID": "TCGA.DD.A4NS",
    "bcr_drug_barcode": "TCGA-DD-A4NS-D59877",
    "bcr_drug_uuid": "36919E0E-FE64-42DA-A63C-712E27F3AF55",
    "form_completion_date": "2014-5-22",
    "pharmaceutical_therapy_drug_name": "TEMOZOLOMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1349,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1425,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "56403463-1727-4C23-A709-DE5F168C4073",
    "patient_ID": "TCGA.ED.A459",
    "bcr_drug_barcode": "TCGA-ED-A459-D48393",
    "bcr_drug_uuid": "F463B232-BE1D-4F17-B6D6-9755593A0B3C",
    "form_completion_date": "2013-10-14",
    "pharmaceutical_therapy_drug_name": "ALVESIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 38,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 103,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "440375D7-CDCD-418A-8992-0A8CA42D290D",
    "patient_ID": "TCGA.EP.A2KA",
    "bcr_drug_barcode": "TCGA-EP-A2KA-D31989",
    "bcr_drug_uuid": "436550BB-A2DE-4EFA-A2F3-702BF8BAAEC5",
    "form_completion_date": "2012-5-14",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 312,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "A8C2AA08-9156-4845-AD77-5E060858C757",
    "patient_ID": "TCGA.FV.A3I0",
    "bcr_drug_barcode": "TCGA-FV-A3I0-D57855",
    "bcr_drug_uuid": "CE83DB6D-029E-4406-84CE-771A43CC490D",
    "form_completion_date": "2014-3-27",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 166,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 586,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "17833039-0D7E-47F0-90E6-8CABAE94C124",
    "patient_ID": "TCGA.FV.A3R2",
    "bcr_drug_barcode": "TCGA-FV-A3R2-D35314",
    "bcr_drug_uuid": "97BF9DCB-DCA9-47B9-BB10-006D47608DAC",
    "form_completion_date": "2013-4-16",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 25,
    "pharmaceutical_tx_ongoing_indicator": false,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "17833039-0D7E-47F0-90E6-8CABAE94C124",
    "patient_ID": "TCGA.FV.A3R2",
    "bcr_drug_barcode": "TCGA-FV-A3R2-D35315",
    "bcr_drug_uuid": "B4669B2E-E16D-482F-A73B-C4BDF8EB5278",
    "form_completion_date": "2013-4-16",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 25,
    "pharmaceutical_tx_ongoing_indicator": false,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "B865DEC4-F051-4FBE-9405-F832FF2010D7",
    "patient_ID": "TCGA.G3.A25S",
    "bcr_drug_barcode": "TCGA-G3-A25S-D45076",
    "bcr_drug_uuid": "A74505A0-B326-4F72-8BBF-BF23538A5960",
    "form_completion_date": "2013-7-4",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "clinical_trial_drug_classification": "SUNITINIB VS SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 313,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 348,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "B865DEC4-F051-4FBE-9405-F832FF2010D7",
    "patient_ID": "TCGA.G3.A25S",
    "bcr_drug_barcode": "TCGA-G3-A25S-D45077",
    "bcr_drug_uuid": "128B2718-B773-4D49-876C-19E3615F5E36",
    "form_completion_date": "2013-7-4",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 351,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 369,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8A14D153-BBF7-4512-A067-976EDFB65F91",
    "patient_ID": "TCGA.G3.A3CG",
    "bcr_drug_barcode": "TCGA-G3-A3CG-D40229",
    "bcr_drug_uuid": "97F4F766-A4E0-4356-BC34-568E8F1B07D7",
    "form_completion_date": "2013-2-14",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 367,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 577,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3A2D7482-C246-411E-841F-71D96E353328",
    "patient_ID": "TCGA.G3.A3CH",
    "bcr_drug_barcode": "TCGA-G3-A3CH-D40096",
    "bcr_drug_uuid": "DC72364F-DDFD-4B54-9477-F29E3142536B",
    "form_completion_date": "2013-2-12",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 717,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "CB8F3C76-DA86-4A1D-977C-44AB399B342A",
    "patient_ID": "TCGA.G3.A3CJ",
    "bcr_drug_barcode": "TCGA-G3-A3CJ-D40237",
    "bcr_drug_uuid": "2579D68E-1CDC-4AB5-8F3B-E366F68B5152",
    "form_completion_date": "2013-2-14",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 346,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 367,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "14201DA5-4446-47BE-AF72-120B7780C6BF",
    "patient_ID": "TCGA.G3.A5SI",
    "bcr_drug_barcode": "TCGA-G3-A5SI-D59275",
    "bcr_drug_uuid": "EF0713F1-6FF0-47EA-92BC-BE9682F0B8A6",
    "form_completion_date": "2014-5-7",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 599,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 733,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4DFF4242-4A53-4F46-B200-7ED83F6B7808",
    "patient_ID": "TCGA.G3.AAV5",
    "bcr_drug_barcode": "TCGA-G3-AAV5-D65944",
    "bcr_drug_uuid": "2DE0F885-BD8A-44B0-88C8-28FC3BA649F3",
    "form_completion_date": "2014-10-1",
    "pharmaceutical_therapy_drug_name": "HEC.1 - SORAFENIB VS SORAFENIB PLUS DOXORUBICIN",
    "clinical_trial_drug_classification": "CHEMOTHERAPY",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 227,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "1EACFCC0-1D05-4441-B3D8-B0790E1C40F1",
    "patient_ID": "TCGA.K7.AAU7",
    "bcr_drug_barcode": "TCGA-K7-AAU7-D63781",
    "bcr_drug_uuid": "09A7B4A1-5613-47F5-977A-6055E11BF104",
    "form_completion_date": "2014-8-18",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1EACFCC0-1D05-4441-B3D8-B0790E1C40F1",
    "patient_ID": "TCGA.K7.AAU7",
    "bcr_drug_barcode": "TCGA-K7-AAU7-D63783",
    "bcr_drug_uuid": "518D97F7-44E3-4366-ACEF-2F1B474EF5DA",
    "form_completion_date": "2014-8-18",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "948A9BBC-60B0-4FB7-A707-76BC41294217",
    "patient_ID": "TCGA.LG.A9QD",
    "bcr_drug_barcode": "TCGA-LG-A9QD-D60838",
    "bcr_drug_uuid": "CD39633C-91A8-4F9F-B06B-08ECCCD2300D",
    "form_completion_date": "2014-6-17",
    "pharmaceutical_therapy_drug_name": "SORAFINIB ( NEXAVAR)",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "10179EFC-A091-4119-8EC2-30DB6269D674",
    "patient_ID": "TCGA.UB.A7MA",
    "bcr_drug_barcode": "TCGA-UB-A7MA-D63551",
    "bcr_drug_uuid": "AA478972-0FC7-49A8-991F-F69895F7266A",
    "form_completion_date": "2014-8-12",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 60,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 207,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "10179EFC-A091-4119-8EC2-30DB6269D674",
    "patient_ID": "TCGA.UB.A7MA",
    "bcr_drug_barcode": "TCGA-UB-A7MA-D63552",
    "bcr_drug_uuid": "4E50B011-3187-4D5E-A047-470F592F99F1",
    "form_completion_date": "2014-8-12",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 60,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 207,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "10179EFC-A091-4119-8EC2-30DB6269D674",
    "patient_ID": "TCGA.UB.A7MA",
    "bcr_drug_barcode": "TCGA-UB-A7MA-D67140",
    "bcr_drug_uuid": "30F9ADEB-3DCA-470C-B321-437EEFC241E7",
    "form_completion_date": "2014-10-31",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 485,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "10179EFC-A091-4119-8EC2-30DB6269D674",
    "patient_ID": "TCGA.UB.A7MA",
    "bcr_drug_barcode": "TCGA-UB-A7MA-D67138",
    "bcr_drug_uuid": "4941EDDA-D11C-43C2-B550-76DAE03C8034",
    "form_completion_date": "2014-10-31",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 485,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "AF1E56AF-410C-4CAD-A4E8-1C6937F1A350",
    "patient_ID": "TCGA.UB.A7MB",
    "bcr_drug_barcode": "TCGA-UB-A7MB-D63686",
    "bcr_drug_uuid": "B5DB5B04-A285-4B4F-9677-5EF63DC2CC7A",
    "form_completion_date": "2014-8-15",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 123,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 168,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AF1E56AF-410C-4CAD-A4E8-1C6937F1A350",
    "patient_ID": "TCGA.UB.A7MB",
    "bcr_drug_barcode": "TCGA-UB-A7MB-D63687",
    "bcr_drug_uuid": "12487060-F921-47CB-B022-758C8911EEB3",
    "form_completion_date": "2014-8-15",
    "clinical_trial_drug_classification": "TORC1/2 INHIBITOR",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 187,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 382,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "AF1E56AF-410C-4CAD-A4E8-1C6937F1A350",
    "patient_ID": "TCGA.UB.A7MB",
    "bcr_drug_barcode": "TCGA-UB-A7MB-D63688",
    "bcr_drug_uuid": "E1751217-035E-4A98-9E0D-0A4B84DF6C7A",
    "form_completion_date": "2014-8-15",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 480,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 510,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AF1E56AF-410C-4CAD-A4E8-1C6937F1A350",
    "patient_ID": "TCGA.UB.A7MB",
    "bcr_drug_barcode": "TCGA-UB-A7MB-D63689",
    "bcr_drug_uuid": "008CFE07-942D-4EAD-B4F7-D21BA4F9BF5D",
    "form_completion_date": "2014-8-15",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 480,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 510,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AF1E56AF-410C-4CAD-A4E8-1C6937F1A350",
    "patient_ID": "TCGA.UB.A7MB",
    "bcr_drug_barcode": "TCGA-UB-A7MB-D63690",
    "bcr_drug_uuid": "0A33C84D-D75A-4EA7-9ABD-8EF3BB748571",
    "form_completion_date": "2014-8-15",
    "clinical_trial_drug_classification": "IMID",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 525,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "5436FAFB-BC16-4450-AC8B-568E1E5EE5FE",
    "patient_ID": "TCGA.WX.AA44",
    "bcr_drug_barcode": "TCGA-WX-AA44-D70641",
    "bcr_drug_uuid": "CF571D27-7579-40DA-8545-E2A600A0CDA1",
    "form_completion_date": "2015-2-27",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 306,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 375,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "39E147C9-2ACB-4BA8-A991-E43E1719B2D8",
    "patient_ID": "TCGA.WX.AA47",
    "bcr_drug_barcode": "TCGA-WX-AA47-D60468",
    "bcr_drug_uuid": "922F00F2-DA7A-4866-B953-CE6B32C5B780",
    "form_completion_date": "2014-6-10",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 331,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 493,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  }
]
